Table 2.

AASLD/ IDSA Recommended HCV Regimens for Treatment-Experienced Patients (adapted from the American Association of the Study of Liver Diseases/ Infectious Diseases Society of America treatment guidance)

	Drug/ Dose	Duration
Treatment-experienced, Non-Cirrhotic
Genotype 1a
	Elbasvir (50 mg)/grazoprevir (100 mg)*	12 weeks
	Elbasvir (50 mg)/grazoprevir (100 mg) + weight-based ribavirin@	12 weeks
	Ledipasvir (90 mg)/sofosbuvir (400 mg)%	12 weeks
	Paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) or + twice-daily dosed dasabuvir (250 mg) + weight-based ribavirin§	12 weeks
	Sofosbuvir (400 mg)/velpatasvir (100 mg)%	12 weeks
	Daclatasvir (60 mg) + sofosbuvir (400 mg)%	12 weeks
	Simeprevir (150 mg) + sofosbuvir (400 mg)	12 weeks
	Elbasvir (50 mg)/grazoprevir (100 mg) + weight-based ribavirin§ˆ$	16 weeks
Genotype 1b
	Elbasvir (50 mg)/ grazoprevir (100 mg)*	12 weeks
	Elbasvir (50 mg)/grazoprevir (100 mg) + weight-based ribavirin@	12 weeks
	Ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks
	Paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) or + twice-daily dosed dasabuvir (250 mg)	12 weeks
	Sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks
	Daclatasvir (60 mg) + sofosbuvir (400 mg)	12 weeks
	Simeprevir (150 mg) + sofosbuvir (400 mg)	12 weeks
Treatment-experienced, Compensated Cirrhotic
Genotype 1a
	Elbasvir (50 mg)/ grazoprevir (100 mg)*	12 weeks
	Elbasvir (50 mg)/grazoprevir (100 mg) + weight-based ribavirin@	12 weeks
	Ledipasvir (90 mg)/sofosbuvir (400 mg) + weight-based ribavirin§≅#	12 weeks
	Sofosbuvir (400 mg)/velpatasvir (100 mg)#	12 weeks
	Elbasvir (50 mg)/ grazoprevir (100 mg) + weight-based ribavirin§ˆ$	16 weeks
	Ledipasvir (90 mg)/sofosbuvir (400 mg)#	24 weeks
	Paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) or + twice-daily dosed dasabuvir (250 mg) + weight-based ribavirin§	24 weeks
	Daclatasvir (60 mg) + sofosbuvir (400 mg)+/− weight-based ribavirin§#	24 weeks
	Simeprevir (150 mg) + sofosbuvir (400 mg)+/− weight-based ribavirin§ ∞	24 weeks
Genotype 1b
	Elbasvir (50 mg)/ grazoprevir (100 mg)	12 weeks
	Elbasvir (50 mg)/grazoprevir (100 mg) + weight-based ribavirin@	12 weeks
	Ledipasvir (90 mg)/sofosbuvir (400 mg) + weight-based ribavirin§≅	12 weeks
	Paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) or + twice-daily dosed dasabuvir (250 mg)	12 weeks
	Sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks
	Ledipasvir (90 mg)/sofosbuvir (400 mg)&	24 weeks
	Daclatasvir (60 mg) + sofosbuvir (400 mg)+/− weight-based ribavirin§	24 weeks
	Simeprevir (150 mg) + sofosbuvir (400 mg)+/− weight-based ribavirin§	24 weeks

^*In the absence of baseline NS5A resistance associated variants (RAVs) at amino acid positions 28, 30, 31, and 93.

^@Regimen specific for protease-inhibitor (boceprevir/telaprevir) and pegylated interferon + ribavirin failures. Patients with RAVs at amino acid positions 28, 30, 31, or 93 should have therapy extended to 16 weeks.

^ˆIn presence of baseline NS5A RAVS at amino acid positions 28, 30, 31, or 93.

^§Weight-based ribavirin dosing: 1000 mg/day in divided doses if body weight of <75 kg; 1200 mg/day in divided doses if body weight of ≥75 kg.

^∞In the absence of baseline NS3/4A Q80K polymorphism.

^≅Regimen can be used for non-cirrhotic sofosbuvir treatment failures.

^&Regimen with the addition of ribavirin can be used for cirrhotic sofosbuvir treatment failures

^%Regimen can be used for non-cirrhotic PI failures, regardless of subtype.

^$Regimen can be used for PI failures, regardless of cirrhosis status

^#Regimen can be used for cirrhotic PI failures, regardless of subtype.